$65 million: Aclaris buying rights to rosacea drug from Allergan

Aclaris Therapeutics has entered into a definitive agreement to acquire the worldwide rights to Rhofade cream, a rosacea treatment, from Allergan for $65 million. Rhofade was approved by the Food and Drug Administration in January 2017 for the topical treatment of persistent facial erythema, or redness, associated with rosacea in adults. The skin disorder afflicts an estimated 16 million people in the United States, according to the National Rosacea Society . “We are excited to acquire Rhofade;…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news